RACI — Responsible, Accountable, Consulted, Informed — is the least glamorous framework in product management, and the one I've reached for most often when a launch is mysteriously stuck. The mystery is almost never effort or talent. It's that three people each believe they own the decision, or worse, each believe someone else does.
Where RACI saved a real launch
The clearest case from my own career: directing the implementation of CaaStle's patented one-time rental system across partner brands like Express, Ralph Lauren, and American Eagle. A new commercial model touching product, engineering, brand partners, legal, finance, and operations — with the brands themselves holding approval power over customer-facing changes. Without explicit ownership mapping, that project would have died in review loops. One page of RACI per workstream — who decides, who executes, who gets consulted before and informed after — kept a dozen stakeholders moving without a single standing meeting added.
How to use RACI without becoming a bureaucrat
- Map decisions, not job titles. The useful unit is "who decides the cancellation copy," not "what does marketing own in general." Abstract RACIs decay in a week; decision-level ones get referenced daily.
- Exactly one A per row. Two accountable names means zero. This is the entire framework, honestly — the rest is formatting.
- Keep C ruthlessly short. Consulted is where velocity dies. Every name in that column adds a review cycle, and most people listed there would rather be informed anyway.
- Deploy it per-initiative, not company-wide. A RACI for the org chart is politics. A RACI for this quarter's launch is a tool. When the launch ships, throw it away.
As a fractional product leader I often build the RACI in week one of an engagement — not because I love matrices, but because it surfaces every ownership conflict in the building within an hour, while everyone can still laugh about it. If your launches keep slipping and the retros keep blaming "communication," ownership ambiguity is the likelier disease, and it's a cheap one to cure.